STOCK TITAN
  1. Home
  2. ENGNW

enGene Therapeutics Warrants (ENGNW) Stock Price, News & Analysis

ENGNW NASDAQ
Published by Stock Titan Data refreshed

What Changed

Price Move History

Daily moves over 5%
103 181 sessions, November 5, 2025 to November 6, 2026
Largest daily move
-90.9% close of May 7, 2026
1-year change
-86.6% closing prices, November 5, 2025 to November 6, 2026
1-month change
+17.2% closing prices, October 5, 2026 to November 6, 2026

Company Description

enGene Therapeutics Warrants (NASDAQ: ENGNW) is classified in the biological products, (no diagnostic substances) industry.

ENGNW has declined 86.6% over the past year. The last closing price was $0.1993.

For FY2025, enGene Therapeutics Warrants reported net income of -$117.3M and diluted earnings per share of $2.29.

This page collects what Stock Titan holds for ENGNW, including price data, latest news, SEC filings, financial highlights, and short interest trends.

Stock Performance

Chart
$0.1993
-
-
Last updated: November 6, 2026 at 16:00
-86.6%
Performance 1 year
-
Market Cap
-
Shares outstanding

enGene Therapeutics Warrants (ENGNW) closed at $0.1993 on November 6, 2026. Over the past 12 months, the price has lost 86.6%.

See what a $1,000 investment in ENGNW would be worth today

Average down calculator for ENGNW

ENGNW Metrics & Rankings

Piotroski F-Score
1/6 Partial
#7,876
Month to date
+9.9%
View ranking
YTD
-93.3%
View ranking

Price returns through November 6, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

Latest News

View All
+7.46%

enGene Announces Name Change to enGene Therapeutics Inc.

-4.17%

enGene Appoints Ryan Daws as Chief Financial Officer

management

enGene Therapeutics Warrants has 2 recent news articles. Of the recent coverage, 1 article coincided with positive price movement and 1 with negative movement. Key topics include management. View all ENGNW news →

SEC Filings

View All

[4] At $1.97 a share, enGene Therapeutics (ENGN) interim medical chief bought 5,102 shares.

[10-Q] Gene-therapy firm enGene (ENGN) halves its staff as losses climb

[8-K] Bladder cancer gene therapy at enGene (ENGN) shows responses as FDA filing nears

[SCHEDULE 13G/A] Perceptive Advisors (NASDAQ: ENGN) discloses 9.99% beneficial stake with warrant cap

[SCHEDULE 13G/A] enGene Holdings (ENGN): Venrock investor group reports 0.0% stake and no voting power

[SCHEDULE 13G/A] Deep Track exits enGene Therapeutics (ENGN) position, reports 0% ownership

[SCHEDULE 13G/A] Raymond Debbane (ENGN) discloses 9.3% enGene stake via Invus and Avicenna

[SCHEDULE 13G/A] Blue Owl Capital Holdings (ENGN) discloses 0.76% warrant-based stake in enGene

[8-K] enGene Therapeutics (NASDAQ: ENGN) maps NMIBC market, $285M cash and BLA plans

[3] Executive options at enGene Therapeutics (ENGN) vesting over 4 years

enGene Therapeutics Warrants has filed 10 recent SEC filings, including 5 Form SCHEDULE 13G/A, 2 Form 8-K, 1 Form 3, 1 Form 4. The most recent filing was submitted on . SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all ENGNW SEC filings →

Financial Highlights

View Full Financials

enGene Therapeutics Warrants reported operating income of -$123.2M in FY2025, and net income was -$117.3M. Diluted earnings per share stood at $2.29. The company generated -$99.2M in operating cash flow. The current ratio was 6.30, measuring current assets divided by current liabilities.

-$117.3M
Net Income (FY2025)
$2.29
Diluted EPS (FY2025)
-$99.2M
Operating Cash Flow
6.30
Current Ratio
-$123.2M
Operating Income
—
Revenue (FY2025)

Upcoming Events

No upcoming events scheduled for ENGNW.

Short Interest History

Last 12 Months

Short interest in enGene Therapeutics Warrants (ENGNW) currently stands at 2.1 thousand shares, up 22.4% from the previous reporting period. Since November 2025, short interest has decreased by 19.0%.

Days to Cover History

Last 12 Months

Days to cover for enGene Therapeutics Warrants (ENGNW) currently stands at 1.0 days. The ratio is the reported short interest divided by the average daily trading volume. Across the settlements charted above, it has ranged from 1.0 to 102.2 days.

ENGNW Company Profile & Sector Positioning

enGene Therapeutics Warrants (ENGNW) and is listed on the NASDAQ.

Frequently Asked Questions

The current stock price of enGene Therapeutics Warrants (ENGNW) is $0.1993 as of November 6, 2026.

The FY2025 net income of enGene Therapeutics Warrants (ENGNW) is -$117.3M, from its most recent completed fiscal year.

The diluted earnings per share (EPS) of enGene Therapeutics Warrants (ENGNW) is $2.29 for FY2025, its most recent completed fiscal year. Learn more about EPS .

The operating cash flow of enGene Therapeutics Warrants (ENGNW) is -$99.2M for FY2025, its most recent completed fiscal year. Learn about cash flow.

The current ratio of enGene Therapeutics Warrants (ENGNW), current assets divided by current liabilities, was 6.30 at the end of FY2025, its most recent completed fiscal year. Learn about liquidity ratios.

The operating income of enGene Therapeutics Warrants (ENGNW) is -$123.2M for FY2025, its most recent completed fiscal year. Learn about operating income.